Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021

Highly specific HDAC6 inhibitors (HDAC6i) demonstrated improved cardiac function in mouse models of heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM) Potential utility of HDAC6 as a target in heart disease was validated using Tenaya’s Precision Medicine platform HDAC6i product candidate TYA-11631 is currently in IND-enabling studies SOUTH SAN FRANCISCO,